Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus first-generation EGFR-TKI versus EGFR-TKI alone in advanced EGFR-mutant NSCLC with slow progression after prior TKI therapy
ChiCTR1800019138Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoint: CT. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019138.